An optimized & streamlined approach for upstream & downstream lentiviral production

Cell and Gene Therapy Insights 2023; 9(5), 739

10.18609/cgti.2023.092

Published: 11 July 2023
FastFacts
Gregory Piscitello, Paul Turiano


Watch the video or view the poster to learn more about:

  • Using DOE to create a robust and defined platform for lentiviral vector manufacturing 
  • Maximizing lentiviral titers through upstream optimization
  • Enriching lentiviral vector recovery through downstream optimization
  • Reducing time to GMP manufacture a clinical product to less than 12 months